Hyrimoz vs. Humira: What’s the Difference?
Humira (adalimumab) is a powerful medication called a TNF-blocker monoclonal antibody. It’s used to treat a wide range of autoimmune conditions, from rheumatoid arthritis and juvenile idiopathic arthritis to psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. Humira is a blockbuster drug, with sales exceeding $20.7 billion in 2021.
Hyrimoz is an adalimumab biosimilar to Humira. Biosimilars are designed to have the same effects as the original drug but may come with different side effects. But what does “biosimilar” even mean?
A biosimilar is a medication that is very similar to another already-approved biological medication. Biosimilars are approved in the same way that generic drugs are approved. The primary reason for biosimilars is to reduce healthcare costs by providing more affordable treatment options.
So how do Hyrimoz and Humira stack up? This article compares the efficacy, safety, administration, and patient considerations for Humira and Hyrimoz. We’ll provide a comprehensive overview to help patients and their healthcare team make informed decisions about treatment.
Read more